OverviewOtonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO® (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, an sNDA has been accepted for filing by the FDA for acute otitis externa (AOE) and a successful End-of-Phase 2 review has been completed with the FDA for acute otitis media with tympanostomy tubes (AOMT). OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial. A program targeting sensorineural hearing loss including age-related hearing loss is in preclinical development. Otonomy’s proprietary formulation technology utilizes a thermosensitive gel and drug microparticles to enable single dose treatment by a physician.
|Recent News||More >>|
|Upcoming Events||More >>|
|There are currently no events scheduled.|
|Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Otonomy Inc posts new information to the site. Just enter your e-mail address and click Submit.|
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|